Cost-Effectiveness of Anti-Epidermal Growth Factor Receptor Therapy Versus Bevacizumab in KRAS Wild-Type (WT), Pan-RAS WT, and Pan-RAS WT Left-Sided Metastatic Colorectal Cancer

Overview of attention for article published in Frontiers in oncology, May 2021

Altmetric Badge

Mentioned by

twitter: 1 X user

Readers on

mendeley: 15 Mendeley

So far, Altmetric has seen 1 X post from an account with 6,542 followers.

New research: Cost-Effectiveness of Anti-Epidermal Growth Factor Receptor Therapy Versus Bevacizumab in KRAS Wild-Type (WT), Pan-RAS WT, and Pan-RAS WT Left-Sided Metastatic Colorectal Cancer: Objectives We aimed to compare the economic value… https://t.co

07 May 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.